C12N 2770/20034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/20034 (Use of virus or viral component as vaccine) appears on 551 US grants and 1,680 published applications in this corpus.
Search patents in C12N- Granted patents
- 551
- Published applications
- 1,680
- Assignees
- 867
- Inventors
- 4,351
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 1 | 0 |
| 1979 | 1 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 2 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 2 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 4 | 0 |
| 1992 | 1 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 3 | 2 |
| 2002 | 3 | 5 |
| 2003 | 3 | 9 |
| 2004 | 0 | 9 |
| 2005 | 2 | 10 |
| 2006 | 5 | 17 |
| 2007 | 5 | 17 |
| 2008 | 12 | 11 |
| 2009 | 6 | 15 |
| 2010 | 8 | 13 |
| 2011 | 3 | 11 |
| 2012 | 2 | 7 |
| 2013 | 8 | 6 |
| 2014 | 4 | 11 |
| 2015 | 3 | 13 |
| 2016 | 11 | 17 |
| 2017 | 15 | 23 |
| 2018 | 17 | 24 |
| 2019 | 17 | 26 |
| 2020 | 20 | 35 |
| 2021 | 42 | 105 |
| 2022 | 52 | 167 |
| 2023 | 55 | 350 |
| 2024 | 71 | 363 |
| 2025 | 84 | 283 |
| 2026 | 55 | 131 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Polypeptides, compositions, and their use to treat or limit development of an infection6 Oct 2026US 12,752,002 B2University of Washington
- Recombinant modified vaccinia virus (MVA) vaccine against coronavirus disease29 Sep 2026US 12,746,282 B2Bavarian Nordic A/S
- High-potency SARS coronavirus 2 antigen and vaccine composition comprising same29 Sep 2026US 12,747,268 B2Korea Research Institute of Chemical Technology
- Variant strain-based coronavirus vaccines22 Sep 2026US 12,741,019 B2ModernaTX, Inc.
- Follicular helper T (TFH) cells specific to SARS-COV-2 virus15 Sep 2026US 12,734,232 B2The University of Osaka
- Spike Protein Based Genetic Vaccines8 Oct 2026US 2026/0306616 A1University of Maryland, Baltimore
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Coronavirus s2 immunogens1 Oct 2026US 2026/0295034 A1The Scripps Research Institute
- Vaccine with reduced anti-vector antigenicity24 Sep 2026US 2026/0284178 A1
Most cited
By later US patents
- Combination PIV3/hMPV RNA vaccines110US 10,064,934 B2ModernaTX, Inc. · 2018
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen109US 9,669,089 B2CureVac AG · 2017
- Recombinant baculovirus and virus-like particle58US 7,527,967 B2Academia Sinica · 2009
- Coronavirus vaccine51US 11,241,493 B2CureVac AG · 2022
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen47US 10,912,826 B2CureVac AG · 2021